Kian Behbakht, MD, MBA

Recognitions

• 5280 Top Docs, 5280 Magazine (2018)
  Recognition by colleagues for excellence in clinical care
• The Emily McClintock-Addlesperger Endowed Professor in Gynecologic Oncology, University of Colorado (2019)
  This is an endowed professorship of $2 million dedicated to the prevention and early diagnosis of ovarian cancer

Publications

• Dinges MM, Jaggessarsingh D, Petersen TH, Behbakht K, Singh M. Lobular endocervial glandular hyperplasia with extensive mucinous differentiation of endometrium and endometrial mucinous adenocarcinoma in situ: a case report and review of the literature. Gynecol Oncol. 122(3):686-8, 2011. PMID: 21605894
• Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Godwin AK, Alpaugh RK. Phase II trial of the mTOR inhibitor temsirolimus and evaluation of circulating tumor cells in persistent or recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 123(1): 19-26, 2011. PMID: 21752435
• Stashwick C, Post MD, Arruda JS, Spillman MA, Behbakht K, Davidson SA, Kelly MG. Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Int J Gynecol Cancer, 21(8):1422-7, 2011. PMID: 21997170
• Wang Y, Sheng Q, Spillman MA, Behbakht K and Gu H. Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. Oncogene Sep 26, 2011 doi: 10.1038/onc.2011.435 (Epub ahead of print) PMID: 21996746
• Kim Y, Guntupalli SR, Lee SJ, Behbakht K, Theodorescu D, Lee JK, Diamond JR. Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer. PLoS One. 2014;9(2):e86532. PubMed PMID: 24505259
• Qamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Thorburn A, Ford HL, Behbakht K. Development and Prognostic Validation of a Polyclonal Antibody to Detect Six1 Homeoprotein in Ovarian Cancer. Accepted Gynecol Oncol 2012.
• Corr BR, Behbakht K, Spillman MA. Gynecologic Biopsy for Molecular Profiling: A Review for the Interventional Radiologist. Semin Intervent Radiol. 2013 Dec;30(4):417-424. PubMed PMID: 24436571
• Anderson C, Qamar L, Davidson S, Spillman M, Behbakht K. Using and ex vivo tumor slice system to investigate experimental therapies in epithelial Ovarian Cancer. Gynecol. Oncol. 123(2): 442, Nov 2011. Presented at the Western Association of Gynecologic Oncology June 2011.
• Guy MS, Cheng G, Post MD, Spillman MA, Behbakht K, Davidson S, Sheeder J, Guntupalli SR. Outcomes of women with atypical glandular cells on preoperative cytology and endometrial cancer. Int J Gynecol Cancer. 2014 Feb;24(2):266-71. PubMed PMID: 24401985
• Embry J, Davis K, Meija N, Davidson SA, Behbakht K. Incidence of venous thromboembolism after robotic surgery for gynecologic malignancy: Is dual prophylaxis necessary. Presented at the 42nd Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, March 2011
• Anderson CK, Wallace S, Guiahi M, Sheeder J, Behbakht K, Spillman MA. Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer. Int J Gynecol Cancer. 2013 Mar;23(3):417-21. PubMed PMID: 23385282
• Wang Y, Sheng Q, Spillman MA, Behbakht K and Gu H. Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. Oncogene Sep 26, 2011 doi: 10.1038/onc.2011.435 (Epub ahead of print) PMID: 21996746
• Matulonis UA, Lee J, Lasonde B, Tew WP, Yehwalashet A, Matei D, Behbakht K, Grothusen J, Fleming G, Lee NK, Arnott J, Bray MR, Fletcher G, Brokx RD, Castonguay V, Mackay H, Sidor CF, Oza AM. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer. 2013 Jan;49(1):121-31. PubMed PMID: 22921155
• Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene. 2012 May 14. doi: 10.1038/onc.2012.164. [Epub ahead of print] PMID 22580613
• Matulonis UA, Lee J, Lasonde B, Tew WP, Yehwalashet A, Matei D, Behbakht K, Grothusen J, Fleming G, Lee NK, Arnott J, Bray MR, Fletcher G, Brokx RD, Castonguay V, Mackay H, Sidor CF, Oza AM. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer. 2012 Aug 21. [Epub ahead of print]
• Anderson CK, Wallace S, Guiahi M, Sheeder J, Behbakht K, Spillman MA. Risk reducing salpingectomy as preventive strategy for pelvic serous cancer. Int J Gynecol Cancer 2013 Mar 23(3): 417-21, PMID 23385282
• Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene. 2013 Mar 14;32(11):1341-50. PubMed PMID: 22580613
• Embry JR, Davidson SA, Behbakht K. Cost comparison between robotic and open hysterectomy for obese women with endometrial cancer. A cost-minimization analysis. Presented at the 43rd Annual Meeting of the Society of Gynecologic Oncology, Austin, TX March 2012
• Kim Y, Behbakht K, Diamond J, Theodorescu D, Lee JK, Personalized chemotherapy for ovarian cancer by integrating genomic data with patients’ clinical information. Presented at the TBC 2012, Seoul, South Korea, September 2012
• Anderson CK, Hicks D, Scarborough H, Vanderlinden L, Tabakoff B, Behbakht K, Spillman MA. Neuropathic Pain Inhibitor Kindolor Augments Efficacy of Gemcitabine and Paclitaxel in Ovarian Cancer Cell Lines Allowing Reduced Chemotherapy, Concentration. Presented at the 44rth Annual Meeting of the Society of Gynecologic Oncology, Los Angeles, CA March 2013
• Guy MS, Cheng G, Post MD, Spillman MA, Behbakht K, Davidson S, Sheeder J, Guntupalli SR. Outcomes of women with atypical glandular cells on preoperative cytology and endometrial cancer. Int J Gynecol Cancer. 2014 Feb;24(2):266-71. PubMed PMID: 24401985
• Guy MS, Qamar L, Behbakht K, Post MD, Sheeder J, Sartorius CA, Spillman MA. Progestin treatment decreases CD133 cancer stem cell populations in endometrial cancer. Gynecol Oncol. 2015 Dec 28. [Epub ahead of print] PubMed PMID: 26731726
• Kim Y, Guntupalli SR, Lee SJ, Behbakht K, Theodorescu D, Lee JK, Diamond JR. Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer. PLoS One. 2014;9(2):e86532. PubMed PMID: 24505259
• Doo DW, Guy MS, Behbakht K, Davidson SA, Sheeder J, Guntupalli SR. Association Between Preoperative Chemotherapy and Postoperative Complications in Patients Undergoing Surgery for Ovarian Cancer. Ann Surg Oncol. 2015 Nov 5. [Epub ahead of print] PubMed PMID: 26542594
• Alvarez RD, Sill MW, Davidson SA, Muller CY, Bender DP, DeBernardo RL, Behbakht K, Huh WK. A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2014 Jun;133(3):433-8. PubMed PMID: 24708919
• Corr BR, Finlay-Schultz J, Rosen RB, Qamar L, Post MD, Behbakht K, Spillman MA, Sartorius CA. Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2015 Nov;25(9):1565-73. PubMed PMID: 26495758
• Guy MS, Sheeder J, Behbakht K, Wright JD, Guntupalli SR. Comparative outcomes in older and younger women undergoing laparotomy or robotic surgical staging for endometrial cancer. Am J Obstet Gynecol. 2015 Nov 17. [Epub ahead of print] PubMed PMID: 26433173
• Zighelboim I, Ali S, Lankes HA, Backes F, Moore K, Mutch D, Robison K, Behbakht K, Waggoner S, Ghebre RG, Pearl M, Ramirez NC, Goodfellow P. Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Sep;138(3):614-9. PubMed PMID: 26144601
• Goldstein CL, Susman E, Lockwood S, Medlin EE, Behbakht K. Awareness of symptoms and risk factors of ovarian cancer in a population of women and healthcare providers. Clin J Oncol Nurs. 2015 Apr;19(2):206-12. PubMed PMID: 25840386
• Ney DE, Messersmith W, Behbakht K. Anti-ma2 paraneoplastic encephalitis in association with recurrent cervical cancer. J Clin Neurol. 2014 Jul;10(3):262-6. PubMed PMID: 25045381
• Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2015 Apr 1;33(10):1180-5. PubMed PMID: 25713428
• Anderson CK, Medlin E, Ferriss AF, Sheeder J, Davidson S, Gibbs R, Behbakht K, Guntupalli SR. Association between gelatin-thrombin matrix use and abscesses in women undergoing pelvic surgery. Obstet Gynecol. 2014 Sep;124(3):589-95. PubMed PMID: 25162261
• Doo DW, Guntupalli SR, Corr BR, Sheeder J, Davidson SA, Behbakht K, Jarrett MJ, Guy MS. Comparative Surgical Outcomes for Endometrial Cancer Patients 65 Years Old or Older Staged With Robotics or Laparotomy. Ann Surg Oncol. 2015 Feb 12. [Epub ahead of print] PubMed PMID: 25672563
• Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H. Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2015 Feb 23. [Epub ahead of print] PubMed PMID: 25713428
• Doo DW, Guntupalli SR, Corr BR, Sheeder J, Davidson SA, Behbakht K, Jarrett MJ, Guy MS. Comparative Surgical Outcomes for Endometrial Cancer Patients 65 Years Old or Older Staged With Robotics or Laparotomy. Ann Surg Oncol. 2015 Oct;22(11):3687-94. PubMed PMID: 25672563
• Guntupalli SR, Sheeder J, Ioffe Y, Tergas A, Wright JD, Davidson SA, Behbakht K, Flink DM. Sexual and Marital Dysfunction in Women With Gynecologic Cancer. Int J Gynecol Cancer. 2017 Jan 26. [Epub ahead of print] PubMed PMID: 28129243
• Dimberg L, Towers CG, Behbakht K, Hotz T, Kim J, Fosmire SP, Porter CC, Tan AC, Thorburn A, Ford HL. A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance. Mol Cancer Res. 2017 Jan 20. [Epub ahead of print] PubMed PMID: 28108622
• Robin TP, Amini A, Schefter TE, Behbakht K, Fisher CM. Disparities in standard of care treatment and associated survival decrement in patients with locally advanced cervical cancer. Gynecol Oncol. 2016 Nov;143(2):319-325. PubMed PMID: 27640961
• Niu H, Shin H, Gao F, Zhang J, Bahamon B, Danaee H, Melichar B, Schilder RJ, Coleman RL, Falchook G, Adenis A, Behbakht K, DeMichele A, Dees EC, Perez K, Matulonis U, Sawrycki P, Huebner D, Ecsedy J. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor. EBioMedicine. 2017 Nov;25:50-57. PubMed PMID: 29122619
• Hicks DA, Galimanis CE, Webb PG, Spillman MA, Behbakht K, Neville MC, Baumgartner HK. Claudin-4 activity in ovarian tumor cell apoptosis resistance and migration. BMC Cancer. 2016 Oct 11;16(1):788. PubMed PMID: 27724921
• Bitler BG, Watson ZL, Wheeler LJ, Behbakht K. PARP inhibitors: Clinical utility and possibilities of overcoming resistance. Gynecol Oncol. 2017 Dec;147(3):695-704. PubMed PMID: 29037806
• Robin TP, Amini A, Schefter TE, Behbakht K, Fisher CM. Brachytherapy should not be omitted when treating locally advanced neuroendocrine cervical cancer with definitive chemoradiation therapy. Brachytherapy. 2016 Nov - Dec;15(6):845-850. PubMed PMID: 27720204
• Zhou K, Spillman MA, Behbakht K, Komatsu JM, Abrahante JE, Hicks D, Schotl B, Odean E, Jones KL, Graner MW, Bemis LT. A method for extracting and characterizing RNA from urine: For downstream PCR and RNAseq analysis. Anal Biochem. 2017 Nov 1;536:8-15. PubMed PMID: 28803886
• Corr BR, Breed C, Sheeder J, Weisdack S, Behbakht K. Bevacizumab induced hypertension in gynecologic cancer: Does it resolve after completion of therapy?. Gynecol Oncol Rep. 2016 Jun 16;17:65-8. PubMed PMID: 27617286
• Morgan RJ Jr, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Percac-Lima S, Pineda M, Plaxe SC, Powell MA, Ratner E, Remmenga SW, Rose PG, Sabbatini P, Santoso JT, Werner TL, Burns J, Hughes M. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Sep;14(9):1134-63. PubMed PMID: 27587625
• Futia GL, Schlaepfer IR, Qamar L, Behbakht K, Gibson EA. Statistical performance of image cytometry for DNA, lipids, cytokeratin, & CD45 in a model system for circulation tumor cell detection. Cytometry A. 2017 Jul;91(7):662-674. PubMed PMID: 28608985
• Guntupalli SR, Sheeder J, Ioffe Y, Tergas A, Wright JD, Davidson SA, Behbakht K, Flink DM. Sexual and Marital Dysfunction in Women With Gynecologic Cancer. Int J Gynecol Cancer. 2017 Mar;27(3):603-607. PubMed PMID: 28129243
• Dimberg LY, Towers CG, Behbakht K, Hotz TJ, Kim J, Fosmire S, Porter CC, Tan AC, Thorburn A, Ford HL. A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. Mol Cancer Res. 2017 Apr;15(4):382-394. PubMed PMID: 28108622
• Osborne RJ, Filiaci VL, Schink JC, Mannel RS, Behbakht K, Hoffman JS, Spirtos NM, Chan JK, Tidy JA, Miller DS. Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia. Obstet Gynecol. 2016 Sep;128(3):535-42. PubMed PMID: 27500329
• Jarrett MJ, Vázquez-Torres A, Frank DN, McCollister BD, Henthorn PK, Ir D, Sheeder J, Guy MS, Anwar HQ, Behbakht K. Influence of Gelatin-Thrombin Matrix Tissue Sealant on Bacterial Colony Formation and Risk of Pelvic Infection. Infect Dis Obstet Gynecol. 2016;2016:2649708. PubMed PMID: 27199534
• Breed C, Hicks DA, Webb PG, Galimanis CE, Bitler BG, Behbakht K, Baumgartner HK. Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel. Mol Cancer Res. 2019 Jan 3. [Epub ahead of print] PubMed PMID: 30606772
• Blake EA, Sheeder J, Behbakht K, Guntupalli SR, Guy MS. Factors Impacting Use of Robotic Surgery for Treatment of Endometrial Cancer in the United States. Ann Surg Oncol. 2016 Oct;23(11):3744-8. PubMed PMID: 27172774
• Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Post MD, Berning AA, Spillman MA, Behbakht K, Bitler BG. CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer. Oncogenesis. 2018 Nov 26;7(11):92. PubMed PMID: 30478317
• Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2018 Oct 18;:e183773. [Epub ahead of print] PubMed PMID: 30347019
• Myers AP, Filiaci VL, Zhang Y, Pearl M, Behbakht K, Makker V, Hanjani P, Zweizig S, Burke JJ 2nd, Downey G, Leslie KK, Van Hummelen P, Birrer MJ, Fleming GF. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Apr;141(1):43-8. PubMed PMID: 27016228
• Guy MS, Qamar L, Behbakht K, Post MD, Sheeder J, Sartorius CA, Spillman MA. Progestin treatment decreases CD133 cancer stem cell populations in endometrial cancer. Gynecol Oncol. 2016 Mar;140(3):518-26. PubMed PMID: 26731726
• Doo DW, Guy MS, Behbakht K, Davidson SA, Sheeder J, Guntupalli SR. Association Between Preoperative Chemotherapy and Postoperative Complications in Patients Undergoing Surgery for Ovarian Cancer. Ann Surg Oncol. 2016 Mar;23(3):968-74. PubMed PMID: 26542594
• Rauh-Hain JA, Brewster WR, Behbakht K. Society of Gynecologic Oncology 2018 Annual Meeting on Women's Cancer: Meeting report. Gynecol Oncol. 2018 Nov;151(2):e7-e9. PubMed PMID: 30146111
• Ramzan AA, Behbakht K, Corr BR, Sheeder J, Guntupalli SR. Minority Race Predicts Treatment by Non-gynecologic Oncologists in Women with Gynecologic Cancer. Ann Surg Oncol. 2018 Nov;25(12):3685-3691. PubMed PMID: 30105439
• Behbakht K, Cohn DE, Straughn JM Jr. Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer. Gynecol Oncol. 2018 Oct;151(1):4-5. PubMed PMID: 30068488
• Guy MS, Sheeder J, Behbakht K, Wright JD, Guntupalli SR. Comparative outcomes in older and younger women undergoing laparotomy or robotic surgical staging for endometrial cancer. Am J Obstet Gynecol. 2016 Mar;214(3):350.e1-350.e10. PubMed PMID: 26433173
• Watson ZL, Yamamoto TM, McMellen A, Kim H, Hughes CJ, Wheeler LJ, Post MD, Behbakht K, Bitler BG. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma. Clin Epigenetics. 2019 Nov 27;11(1):165. PubMed PMID: 31775874
• O'Cearbhaill RE, Deng W, Chen LM, Lucci JA 3rd, Behbakht K, Spirtos NM, Muller CY, Benigno BB, Powell MA, Berry E, Tewari KS, Hanjani P, Lankes HA, Aghajanian C, Sabbatini PJ. A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384)  OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study. Gynecol Oncol. 2019 Dec;155(3):393-399. PubMed PMID: 31653510
• Park PH, Yamamoto TM, Li H, Alcivar AL, Xia B, Wang Y, Bernhardy AJ, Turner KM, Kossenkov AV, Watson ZL, Behbakht K, Casadei S, Swisher EM, Mischel PS, Johnson N, Bitler BG. Amplification of the mutation-carrying BRCA2 allele promotes RAD51 loading and PARP inhibitor resistance in the absence of reversion mutations. Mol Cancer Ther. 2019 Oct 1. [Epub ahead of print] PubMed PMID: 31575654
• Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA III, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Canc Netw. 2019 Aug 1;17(8):896-909. PubMed PMID: 31390583
• Adams CL, Dimitrova I, Post MD, Gibson L, Spillman MA, Behbakht K, Bradford AP. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma. Exp Mol Pathol. 2019 Oct;110:104284. PubMed PMID: 31301306
• Ramzan AA, Bitler BG, Hicks D, Barner K, Qamar L, Behbakht K, Powell T, Jansson T, Wilson H. Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells. Mol Cell Biochem. 2019 Nov;461(1-2):37-46. PubMed PMID: 31292831
• Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, Bitler BG. Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Mol Carcinog. 2019 Oct;58(10):1770-1782. PubMed PMID: 31219654
• Moroney MR, Davies KD, Wilberger AC, Sheeder J, Post MD, Berning AA, Fisher C, Lefkowits C, Guntupalli SR, Behbakht K, Corr BR. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers. Gynecol Oncol. 2019 Jun;153(3):517-520. PubMed PMID: 30910249
• Breed C, Hicks DA, Webb PG, Galimanis CE, Bitler BG, Behbakht K, Baumgartner HK. Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel. Mol Cancer Res. 2019 Mar;17(3):741-750. PubMed PMID: 30606772
• Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019 Jan 1;5(1):e183773. PubMed PMID: 30347019
• Jordan KR, Sikora MJ, Slansky JE, Minic A, Richer JK, Moroney MR, Hu J, Wolsky RJ, Watson ZL, Yamamoto TM, Costello JC, Clauset A, Behbakht K, Kumar TR, Bitler BG. The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval. Clin Cancer Res. 2020 Dec 1;26(23):6362-6373. PubMed PMID: 32928797
• Corr BR, Moroney M, Sheeder J, Eckhardt SG, Sawyer B, Behbakht K, Diamond JR. Survival and clinical outcomes of patients with ovarian cancer who were treated on phase 1 clinical trials. Cancer. 2020 Oct 1;126(19):4289-4293. PubMed PMID: 32697381
• Johnson S, Renz M, Wheeler L, Diver E, Dorigo O, Litkouhi B, Behbakht K, Howitt B, Karam A. Vulvar sarcoma outcomes by histologic subtype: a Surveillance, Epidemiology, and End Results (SEER) database review. Int J Gynecol Cancer. 2020 Aug;30(8):1118-1123. PubMed PMID: 32641392
• Guntupalli SR, Brennecke A, Behbakht K, Tayebnejad A, Breed CA, Babayan LM, Cheng G, Ramzan AA, Wheeler LJ, Corr BR, Lefkowits C, Sheeder J, Matsuo K, Flink D. Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial. JAMA Netw Open. 2020 Jun 1;3(6):e207410. PubMed PMID: 32589230
• Sawyer BT, Qamar L, Yamamoto TM, McMellen A, Watson ZL, Richer JK, Behbakht K, Schlaepfer IR, Bitler BG. Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression. Mol Cancer Res. 2020 Jul;18(7):1088-1098. PubMed PMID: 32198139
• Ross ME, Scott S, Behbakht K, Harper T. Spontaneous dichorionic-diamniotic twins in a noncommunicating uterine horn: A case report. Case Rep Womens Health. 2020 Apr;26:e00177. PubMed PMID: 32055454
• Clauset A, Behbakht K, Bitler BG. Decoding the dynamic tumor microenvironment. Sci Adv. 2021 Jun;7(23). PubMed PMID: 34088677
• Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Feb 2;19(2):191-226. PubMed PMID: 33545690
• Essel KG, Behbakht K, Lai T, Hand L, Evans E, Dvorak J, Ding K, Konecny G, Moore KN. PARPi after PARPi in epithelial ovarian cancer. Gynecol Oncol Rep. 2021 Feb;35:100699. PubMed PMID: 33537389
• Jordan KR, Sikora MJ, Slansky JE, Minic A, Richer JK, Moroney MR, Hu J, Wolsky RJ, Watson ZL, Yamamoto TM, Costello JC, Clauset A, Behbakht K, Kumar TR, Bitler BG. The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval. Clin Cancer Res. 2020 Dec 1;26(23):6362-6373. PubMed PMID: 32928797
• McMellen A, Yamamoto TM, Qamar L, Sanders BE, Nguyen LL, Ortiz Chavez D, Bapat J, Berning A, Post MD, Johnson J, Behbakht K, Nurmemmedov E, Chuong EB, Bitler BG. ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer. Mol Cancer Res. 2023 Jan 3;21(1):3-13. PubMed PMID: 36149636
• Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA III, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L. NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022. J Natl Compr Canc Netw. 2022 Sep;20(9):972-980. PubMed PMID: 36075393
• Yamamoto TM, Webb PG, Davis DM, Baumgartner HK, Woodruff ER, Guntupalli SR, Neville M, Behbakht K, Bitler BG. Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors. Mol Cancer Ther. 2022 Apr 1;21(4):647-657. PubMed PMID: 35373300
• Haag J, Sanders BE, Walker Keach J, Lefkowits C, Sheeder J, Behbakht K. Impact of blinding interviewers to written applications on ranking of Gynecologic Oncology fellowship applicants from groups underrepresented in medicine. Gynecol Oncol Rep. 2022 Feb;39:100935. PubMed PMID: 35141387

Practice Locations

• University of Colorado Hospital
• Denver Health Medical Center

• University of Colorado Cancer Center

Specialty Information

• Obstetrics and Gynecology, Board Certification (2000, 2016)
• Gynecologic Oncology, Board Certification (2002, 2016)

• Surgery - Robotic Surgery
• Cancers - Gynecologic Cancer
• Cancers - Ovarian Cancer
• Cancers
• Surgery